Expand COGT Menu
COGT MENU

COGT Latest Press Releases

-- February 17, 2026 --

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results Globe Newswire 8:00 AM

-- February 10, 2026 --

Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting Globe Newswire 8:00 AM

-- January 26, 2026 --

Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST) Globe Newswire 8:00 AM

-- January 20, 2026 --

Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR) Globe Newswire 8:00 AM

-- January 12, 2026 --

Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio Globe Newswire 8:00 AM

-- January 6, 2026 --

Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference Globe Newswire 8:00 AM

-- December 30, 2025 --

Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis Globe Newswire 8:00 AM

-- December 8, 2025 --

Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) Globe Newswire 7:30 AM

-- December 6, 2025 --

Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH) Globe Newswire 9:30 AM

-- November 14, 2025 --

Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference Globe Newswire 8:00 AM

-- November 11, 2025 --

Cogent Biosciences Announces Pricing of Concurrent Public Offerings of Common Stock and 1.625% Convertible Senior Notes Due 2031 Globe Newswire 11:16 PM

-- November 10, 2025 --

Cogent Biosciences Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock Globe Newswire 4:01 PM
Cogent Biosciences Reports Positive Results from Bezuclastinib PEAK Phase 3 Trial in Gastrointestinal Stromal Tumors (GIST) Globe Newswire 7:00 AM

-- November 3, 2025 --

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2025 Financial Results Globe Newswire 9:01 AM
Cogent Biosciences Announces Multiple Presentations at the 67th Annual American Society of Hematology (ASH) Meeting Globe Newswire 9:00 AM

-- October 24, 2025 --

Cogent Biosciences Announces KRAS Poster Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Globe Newswire 12:30 PM

-- October 20, 2025 --

Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib Globe Newswire 8:32 AM

-- September 29, 2025 --

Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM
Market Data Delayed 15 Minutes